These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 30352240

  • 1. Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells.
    Yang F, Wang F, Liu Y, Wang S, Li X, Huang Y, Xia Y, Cao C.
    Life Sci; 2018 Nov 15; 213():149-157. PubMed ID: 30352240
    [Abstract] [Full Text] [Related]

  • 2. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulforaphane in human breast cancer cells.
    Cao C, Wu H, Vasilatos SN, Chandran U, Qin Y, Wan Y, Oesterreich S, Davidson NE, Huang Y.
    Int J Cancer; 2018 Sep 15; 143(6):1388-1401. PubMed ID: 29633255
    [Abstract] [Full Text] [Related]

  • 3. Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in Vivo.
    Li HC, Xia ZH, Chen YF, Yang F, Feng W, Cai H, Mei Y, Jiang YM, Xu K, Feng DX.
    Cell Physiol Biochem; 2017 Sep 15; 43(5):1829-1840. PubMed ID: 29050003
    [Abstract] [Full Text] [Related]

  • 4. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    Breast Cancer Res; 2015 Mar 07; 17():33. PubMed ID: 25888415
    [Abstract] [Full Text] [Related]

  • 5. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW, Yeh YL, Wang YC, Huang WJ, Ho SY, Lin P, Wang YJ.
    Mol Cancer; 2016 Jun 10; 15(1):46. PubMed ID: 27286975
    [Abstract] [Full Text] [Related]

  • 6. Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Smoots SG, Schreiber AR, Jackson MM, Bagby SM, Dominguez ATA, Dus ED, Binns CA, MacBeth M, Whitty PA, Diamond JR, Pitts TM.
    Breast Cancer Res; 2024 Mar 01; 26(1):35. PubMed ID: 38429789
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
    Zhang J, Chen X, Chen G, Wang H, Jia L, Hao Y, Yao D.
    Int J Biol Macromol; 2023 Nov 01; 251():126348. PubMed ID: 37586623
    [Abstract] [Full Text] [Related]

  • 11. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R, Balusu R, Fiskus W, Mudunuru U, Venkannagari S, Chauhan L, Smith JE, Hembruff SL, Ha K, Atadja P, Bhalla KN.
    Mol Cancer Ther; 2012 Apr 01; 11(4):973-83. PubMed ID: 22367781
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Toosendanin and isotoosendanin suppress triple-negative breast cancer growth via inducing necrosis, apoptosis and autophagy.
    Zhang J, Yang F, Mei X, Yang R, Lu B, Wang Z, Ji L.
    Chem Biol Interact; 2022 Jan 05; 351():109739. PubMed ID: 34742683
    [Abstract] [Full Text] [Related]

  • 15. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo.
    Chiu HW, Yeh YL, Wang YC, Huang WJ, Chen YA, Chiou YS, Ho SY, Lin P, Wang YJ.
    PLoS One; 2013 Jan 05; 8(10):e76340. PubMed ID: 24130769
    [Abstract] [Full Text] [Related]

  • 16. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis.
    Wawruszak A, Luszczki JJ, Kalafut J, Okla K, Halasa M, Rivero-Muller A, Stepulak A.
    Int J Mol Sci; 2019 Jul 26; 20(15):. PubMed ID: 31357442
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibition of aerobic glycolysis enhances the anti-tumor efficacy of Zoptarelin Doxorubicin in triple-negative breast cancer cells.
    Gründker C, Wokoun U, Hellriegel M, Emons G.
    J Obstet Gynaecol Res; 2019 Jul 26; 45(7):1334-1342. PubMed ID: 31016845
    [Abstract] [Full Text] [Related]

  • 19. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    Biomed Pharmacother; 2018 Mar 26; 99():543-551. PubMed ID: 29902865
    [Abstract] [Full Text] [Related]

  • 20. Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
    Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB.
    BMC Cancer; 2014 Nov 19; 14():847. PubMed ID: 25410881
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.